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ABSTRACT
Introduction
Service members (SMs) in the United States (U.S.) Armed Forces have diabetes mellitus at a rate of 2–3%. Despite
having a chronic medical condition, they have deployed to environments with limited medical support. Given the scarcity
of data describing how they fare in these settings, we conducted a retrospective study analyzing the changes in glycated
hemoglobin (HbA1c) and body mass index (BMI) before and after deployment.
Materials and Methods
SMs from the U.S. Army, Air Force, Navy, and Marine Corps with diabetes who deployed overseas were identified
through the Military Health System (MHS) Management Analysis and Reporting Tool and the Defense Manpower
Data Center. Laboratory and pharmaceutical data were obtained from the MHS Composite Health Care System and
the Pharmacy Data Transaction Service, respectively. Paired t-tests were conducted to calculate changes in HbA1c and
BMI before and after deployment.
Results
SMs with diabetes completed 11,325 deployments of greater than 90 days from 2005 to 2017. Of these, 474 (4.2%) SMs
had both HbA1c and BMI measurements within 90 days prior to departure and within 90 days of return. Most (84.2%)
required diabetes medications: metformin in 67.3%, sulfonylureas in 19.0%, dipeptidyl peptidase-4 inhibitors in 13.9%,
and insulin in 5.5%. Most SMs deployed with an HbA1c < 7.0% (67.1%), with a mean predeployment HbA1c of 6.8%.
Twenty percent deployed with an HbA1c between 7.0 and 7.9%, 7.2% deployed with an HbA1c between 8.0 and 8.9%,
and 5.7% deployed with an HbA1c of 9.0% or higher. In the overall population and within each military service, there
was no significant change in HbA1c before and after deployment. However, those with predeployment HbA1c < 7.0%
experienced a rise in HbA1c from 6.2 to 6.5% (P < 0.001), whereas those with predeployment HbA1c values ≥7.0%
experienced a decline from 8.0 to 7.5% (P < 0.001). Those who deployed between 91 and 135 days had a decline in
HbA1c from 7.1 to 6.7% (P = 0.010), but no significant changes were demonstrated in those with longer deployment
durations. BMI declined from 29.6 to 29.3 kg/m2 (P < 0.001), with other significant changes seen among those in the
Army, Navy, and deployment durations up to 315 days.
Conclusions
Most SMs had an HbA1c < 7.0%, suggesting that military providers appropriately selected well-managed SMs for
deployment. HbA1c did not seem to deteriorate during deployment, but they also did not improve despite a reduction
in BMI. Concerning trends included the deployment of some SMs with much higher HbA1c, utilization of medications
with adverse safety profiles, and the lack of HbA1c and BMI evaluation proximal to deployment departures and returns.
However, for SMs meeting adequate glycemic targets, we demonstrated that HbA1c remained stable, supporting the
notion that some SMs may safely deploy with diabetes. Improvement in BMI may compensate for factors promoting
hyperglycemia in a deployed setting, such as changes in diet and medication availability. Future research should analyze
in a prospective fashion, where a more complete array of diabetes and readiness-related measures to comprehensively
evaluate the safety of deploying SMs with diabetes.
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METHODS
Data were gathered from the Military Health System (MHS)
Management Analysis and Reporting Tool, which contains
administrative healthcare records from inpatient and outpatient military treatment facilities and civilian facilities where
the SMs received treatment funded by TRICARE. Additional
MHS data were collected from the Defense Manpower Data
Center and the Pharmacy Data Transaction Service. Laboratory data were retrieved from the MHS Composite Health Care
System.

MILITARY MEDICINE, Vol. 185, March/April 2020

The cohort was selected to include active duty SMs from
the U.S. Army, Air Force, Navy, and Marine Corps with at
least one deployment lasting greater than 90 days between
January 1, 2005 and December 31, 2017, and a diabetes diagnosis during the deployment dates. The diabetes diagnosis was
gathered from claims and/or encounter data as documented
through the Healthcare Effectiveness Data and Information
Set. The first day of the first month that a SM registered a
diagnosis of diabetes was considered the first day that a SM
had diabetes. Only deployments that began after that day were
included in this analysis. For the purpose of this analysis,
members of reserve units (Army Reserve, Army National
Guard, Air Force Reserve, Air National Guard, Naval Reserve,
and Marine Corps Reserve) were considered active duty members of their respective branches while they were activated.
SMs who became pregnant or received a pregnancy related
diagnosis between 6 months before their deployment began
and 6 months after their deployment ended were excluded
from our analysis.
BMI measurements and blood samples for HbA1c were
obtained at military treatment facilities for either pre or postdeployment medical evaluations, or other healthcare encounters that may or may not have been related to deployment.
Only BMI and HbA1c results recorded in the period of 90 days
before deployment or 90 days after return were included.
If more than one measurement were collected in the pre or
postdeployment periods, the maximum value in each period
was used for the analysis.
ICD-9 and ICD-10 diagnosis codes were used to determine the presence of comorbidities within the 90-day period
before deployment. Similarly, therapeutic class codes from the
American Hospital Formulary Service were used to determine
the presence of a prescription for diabetes-related medications
in the 90-day period before deployment. These flags were
computed for each individual and each deployment.
Data were gathered using Microsoft SQL Server 2012.
Analysis was conducted using R version 3.5.2. To build a
description of the population, univariate measures were made
for each of the recorded measures. Pairwise t-tests were then
used to determine if there were changes in HbA1c and BMI
scores in the periods before or after deployment.

RESULTS
From 2005 to 2017, SMs with diabetes from the U.S. Army,
Air Force, Navy, and Marine Corps participated in 11,325
deployments lasting greater than 90 days. Our analysis
focused on those who had both an HbA1c and BMI checked
within 90 days of deployment and within 90 days of return,
of which 474 (4.2%) qualified (Fig. 1); their demographic
information is presented in Table I. The majority of the total
population (79.6%) lacked any HbA1c checks within the
relevant time intervals and only 680 (6.0%) had an HbA1c
checked at both intervals. The most common age group
was 41–50 years old, followed by 31–40 years old. The
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INTRODUCTION
Continuation of military service is possible among active duty
service members (SMs) in the United States (U.S.) Armed
Forces when they develop chronic medical conditions, such
as diabetes mellitus (henceforth “diabetes”). Multiple factors
affect this decision, including occupation and severity of disease. A study from 2006 to 2010 examining prevalence of
diabetes among SMs demonstrated that, among those age
45–64, 2.9% of men and 2.2% of women had diabetes.1
Although most military providers are aware that duty restrictions and retainability standards apply for any SM with a
chronic medical condition, it is not as ubiquitously known
that some have not only been retained in active duty but have
also deployed. A waiver enabling deployment is permissible
as outlined in the Department of Defense Instruction (DoDI)
6490.07 whereby select members with diabetes can participate in “contingency deployments.” DoDI 6490.07 defines
“contingency deployments” as “a deployment that is limited
to outside the continental U.S., over 30 days in duration,
and in a location with medical support from only nonfixed
(temporary) military medical treatment facilities.”2 The DoDI
requires a minimum of a medical record review by a trained
DoD healthcare provider to determine whether a SM with a
chronic medical condition can deploy based on the severity
and stability of the condition, as well as the environment and
other anticipated requirements in deployment. It is logical
that diabetes is specifically identified in the DoDI as a highrisk condition since both disease decompensation and certain
diabetes medications can cause incapacitation.
The deliberations surrounding the decision to deploy a SM
with diabetes may be a difficult one for a military provider,
compounded by the scarcity of data depicting how SMs with
diabetes fare in deployment. There are multiple factors to
consider, including the achievement of glycemic targets prior
to deployment, potential for decompensation, presence of
comorbidities, and safety profiles of medications. Our group
has previously published findings on the pre and postdeployment glycated hemoglobin (HbA1c) among U.S. Air Force
SMs with diabetes3 , but similar studies and data on other
services are lacking. In this study, we analyzed HbA1c values
and body mass indices (BMI) before and after an overseas
deployment among SMs from the U.S. Army, Air Force, Navy,
and Marine Corps.

Effect of Deployments on Diabetes and BMI

preponderance of male and enlisted SMs were expected given
the gender and rank distribution of the U.S. Armed Forces.
Those in the Army deployed for an average duration of
284 days, Air Force personnel for 169 days, Navy personnel
for 203 days, and Marines Corps personnel for 198 days.
The majority of the population required diabetes medications (84.2%), of which metformin was the most common
(67.3%), followed by sulfonylureas (19.0%) and dipeptidyl
peptidase-4 (DPP-4) inhibitors (13.9%). Insulin-users comprised 5.5% of the population. Approximately, a third had
comorbid hypertension and/or hyperlipidemia, but only 1.0%
or less had any microvascular complications. In comparison to
this group, those who lacked any HbA1c data had lower rates
of hypertension (5%) and hyperlipidemia (5%). Likewise,
rates of microvascular complications were <1%.
The mean predeployment HbA1c and BMI were 6.8 and
29.6 kg/m2 , respectively. The majority (67.1%) deployed
with HbA1c < 7.0%, but with a BMI in the overweight or
obese range. For the total population, there was no significant
change in HbA1c pre and postdeployment (P = 0.885).
Likewise, no significant change in HbA1c was seen when the
population was analyzed separately based on military service
(Fig. 2). However, when the population was dichotomized
into those with HbA1c < 7.0% and ≥7.0%, statistically
significant changes emerged. Those with a predeployment
HbA1c < 7.0% experience a statistically significant rise
in HbA1c (6.2–6.5%, P < 0.001), whereas those with
HbA1c ≥ 7.0% experienced a statistically significant decline
(8.0–7.5%, P < 0.001).
Among the 680 SMs who had a pre and postdeployment
HbA1c only (no BMI), the mean HbA1c remained at 6.9%
(P = 0.471). When categorized by service, however, Army
SMs demonstrated a significant rise in HbA1c from 6.8 to
7.0% (P = 0.021), which differed from the findings within
the population with both HbA1c and BMI data. Otherwise,
there were no significant changes within the other services
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(Air Force, 6.8–6.6%, P = 0.142; Navy, 7.1–6.9%, P = 0.086;
and Marines, 7.2–8.0%, P = 0.056).
For the total population, there was a statistically significant
decline in BMI (29.6 to 29.3 kg/m2 , P < 0.001). Members
from the Army and Navy appear to have driven this decline
(30.1–29.7 kg/m2 , P < 0.001 and 29.8–29.3 kg/m2 , P = 0.047,
respectively), whereas no significant change in BMI was seen
from those in the Air Force (28.8–28.5 kg/m2 , P = 0.228)
and the Marine Corps (27.7–26.8 kg/m2 , P = 0.114)
(Fig. 3).
HbA1c and BMI were also analyzed based on the following deployment durations: 91–135 days, 136–225 days, 226–
315 days, and>315 days. The number of SMs in each category
was 80, 198, 82, and 114, respectively. HbA1c declined from
7.1 to 6.7% (P = 0.010) in those who deployed for 90–
135 days, but other duration categories did not demonstrate
any significant changes. In the latter categories, both mean
pre and postdeployment HbA1c remained less than 7.0%. BMI
declined significantly in all categories of deployment durations except for greater than 315 days (91–135 days: 29.4–
29.1 kg/m2 , P = 0.042; 136–225 days: 29.9–29.4 kg/m2 ,
P = 0.029; 226–315 days: 29.9–29.4 kg/m2 , P = 0.009; and
>315 days: 30.0–29.7 kg/m2 , P = 0.085).
DISCUSSION
In this retrospective analysis of HbA1c levels and BMI
obtained before and after overseas deployments among active
duty SMs with diabetes, we found no significant change
in HbA1c and a significant decline in BMI among those
with available data. Recognizing that medical deployment
screenings may have relied on HbA1c checks only, we
also analyzed those with HbA1c but lacking BMI data.
Like the findings of SMs with both HbA1c and BMI, no
significant difference emerged except for those in the Army
who experienced a rise in HbA1c.
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FIGURE 1. Case selection for analysis, by service, followed by presence of HbA1c and BMI data. ∗ percentage by service.
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TABLE I. Characteristics of the Study Sample with Paired Pre- and Post-HbA1c and BMI Prior to Deployment
Variable
N

Army
N

(%)

252

N

Air Force
(%)

115

Navy
N

(%)

99

Marine Corps
N
(%)
8

(84.4)
(15.6)

209
43

(82.9)
(17.1)

96
19

(83.5)
(16.5)

87
12

(87.9)
(12.1)

8
0

(100)
(0)

(6.1)
(35.7)
(48.5)
(9.7)

14
74
131
33

(5.6)
(29.4)
(52.0)
(13.1)

9
51
45
10

(7.8)
(44.3)
(39.1)
(8.7)

5
38
53
3

(5.1)
(38.4)
(53.5)
(3.0)

1
6
1
0

(12.5)
(75)
(12.5)
(0)

(25.1)
(73.2)
(1.7)

72
176
4

(28.6)
(69.8)
(1.6)

26
88
1

(22.6)
(76.5)
(0.9)

18
78
3

(18.2)
(78.8)
(3.0)

3
5
0

(37.5)
(62.5)
(0)

(31.9)
(36.3)
(1.1)
(0.2)
(0.8)

73
82
4
1
4

(29.0)
(32.5)
(1.6)
(0.4)
(1.6)

38
39
1
0
0

(33.0)
(33.9)
(0.9)
(0)
(0)

37
48
0
0
0

(37.4)
(48.5)
(0)
(0)
(0)

3
3
0
0
0

(37.5)
(37.5)
(0)
(0)
(0)

(67.3)
(19.0)
(13.9)
(11.8)
(5.5)
(1.9)
(0.2)
(0)
(0)

165
41
32
21
17
7
0
0
0

(65.5)
(16.3)
(12.7)
(8.3)
(6.7)
(2.8)
(0)
(0)
(0)

71
22
21
11
5
1
0
0
0

(61.7)
(19.1)
(18.3)
(9.6)
(4.3)
(0.9)
(0)
(0)
(0)

79
26
12
21
3
1
1
0
0

(79.8)
(26.3)
(12.1)
(21.2)
(3.0)
(1.0)
(1.0)
(0)
(0)

4
1
1
3
1
0
0
0
0

(50.0)
(12.5)
(12.5)
(37.5)
(12.5)
(0)
(0)
(0)
(0)

(67.1)
(20.0)
(7.2)
(5.7)

170
49
21
12

(67.5)
(19.4)
(8.3)
(4.8)

84
19
7
5

(73.0)
(16.5)
(6.1)
(4.3)

58
27
4
10

(58.6)
(27.3)
(4.0)
(10.1)

6
0
2
0

(75.0)
(0)
(25.0)
(0)

(12.9)
(44.7)
(42.4)

24
113
115

(9.5)
(44.8)
(45.6)

23
51
41

(20.0)
(44.3)
(35.7)

12
45
42

(12.1)
(45.5)
(42.4)

2
3
3

(25.0)
(37.5)
(37.5)

∗ Also known as metformin.
† Dipeptidyl peptidase-4.
# Also known as glucagon-like peptide 1 receptor agonists.
‡ Sodium-glucose transport protein 2.

Most of the SMs deployed with an HbA1c < 7.0% and did
not have microvascular complications, suggesting that, from
a glycemic standpoint, military providers were discriminating
SMs appropriately for deployment. An HbA1c < 7.0%
is an appropriate target according to prevailing diabetes
clinical practice guidelines and expert opinion from military
endocrinologists,4–7 especially prior to deployment given
the uncertainty of clinical surveillance availability. As such,
only those who participated in the shortest duration category
(91–135 days) had a mean predeployment HbA1c that was
>7.0%, which may reflect limitations that were made for this
group during the deployment screening process. Nevertheless,
the mean HbA1c in this group was just above goal at 7.1%

MILITARY MEDICINE, Vol. 185, March/April 2020

and declined to a mean HbA1c of 6.7% at the end of the
deployment, providing further insight for the military provider
who may make deployment clearance decisions for SMs with
HbA1c above ideal targets.
The vast majority of SMs required a medication for diabetes, including a few on insulin, which is a medication of
special interest in a deployed setting due to its refrigerated
storage requirements and potential to cause hypoglycemia.
The second most common medication type, sulfonylureas, is
also unfavorable due to its association with hypoglycemia, but
its prevalence was expected given the prevailing prescribing
practices during our study interval.8,9 However, metformin’s
place as the most common prescribed medication is in keeping
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Total
474
Gender
Male
400
Female
74
Age groups
18–30
29
31–40
169
41–50
230
50+
46
Rank category
Officer
119
Enlisted
347
Unknown
8
Comorbidities
Hypertension
151
Lipid disorders
172
Retinopathy
5
Nephropathy
1
Neuropathy
4
Prescriptions (therapeutic class)
Biguanide∗
319
Sulfonylurea
90
66
DPP4-inhibitor†
Thiazolidinedione
56
Insulin
26
Incretin mimetic#
9
Meglinitide
1
Amylin mimetic
0
SGLT-2 inhibitor‡
0
HbA1c
<7%
318
7–7.9%
95
8–8.9%
34
≥9%
27
BMI (kg/m2 )
18.5–24.9
61
25–29.9
212
≥30
201

Overall
(%)

Effect of Deployments on Diabetes and BMI

FIGURE 3. BMI before and after deployment. Data represents mean BMI +/− SD. ∗ P < 0.05.

with clinical practice guidelines given its high efficacy, oral
delivery, and favorable safety profile.4–6 The paucity of SMs
on DPP4-inhibitors, glucagon-like peptide 1 receptor agonists (GLP-1 RA, also called incretin mimetic), and sodiumglucose transport protein 2 (SGLT2) inhibitors was likely due
to their novelty and injectable delivery in the case of GLP-1
RA.8,9
The results of this study differed from a prior retrospective
analysis conducted by the same authors comprised of U.S.
Air Force personnel only. In contrast to the current study, that
study demonstrated a statistically significant improvement
in HbA1c after deployment. However, BMI reduction was
concordant.3 The discordance in HbA1c results, even when
comparing the Air Force cohort only, was likely related to
the differences in population selection methodology and data
analysis. In the previous study, the analysis was not limited
to those with concurrent HbA1c and BMI data; having either
a pre- and post-HbA1c or a pre- and post-BMI satisfied the
inclusion criteria. Change in HbA1c was analyzed without
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regard for BMI and vice versa. However, in the current study,
the analysis was limited to those with concurrent pre- and postHbA1c and BMI data. Additionally, the current study limited
the population to those who deployed overseas, whereas that
information was not available in the prior study. By excluding
those who deployed within the continental U.S., we avoided
the inclusion of a group who had access to diabetes care
comparable to in-garrison care, which could have skewed the
analysis.
Few other reports exist depicting how SMs with diabetes
manage their condition while performing military-related
activities. Medical staff from the armed forces of the U.S.,
Canada, Finland, and Israel has published case reports and
small observational studies on glycemic control during
various military activities, ranging from basic military training
to combat aviation.10–15 A study from Finland followed newly
accessed SMs with type 1 diabetes over a 12-month period
and reported a modest, but statistically significant, increase in
HbA1c by 0.6% (P = 0.007).14 A diabetes telemedicine clinic

MILITARY MEDICINE, Vol. 185, March/April 2020
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FIGURE 2. HbA1c before and after deployment. Data represent mean HbA1c +/− SD. † [10.93 × HbA1c%]–23.5 = mmol/mol.
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that they receive appropriate care when they return. A medical
assessment that includes standard of care lab work for SMs
with diabetes (and other chronic conditions) should be routine
practice pre and postdeployment. Fourth, it is noteworthy
that most SMs with diabetes are deploying with medications,
which are relatively safe. Metformin is a preferred agent in
type 2 diabetes as it is rarely associated with hypoglycemia.
There were only a few deployed members (5.5% of the analysis group) using insulin, which should be reserved only in
situations with reliable and predictable resources for refills
and refrigerated storage. Choi’s report, however, suggests that
SMs using insulin can perform well with robust support in a
variety of military scenarios.15
While this is the first study to our knowledge looking
this broadly at the scope of diabetes in relation to military
deployments, we acknowledge several limitations of our analysis. First, since our study included only those SMs with
diabetes who had both HbA1c and BMI within 90 days pre
and postdeployment, our analysis only represents a small
proportion (4.2%) of the entire group of SMs who deployed
with this condition. Extracting those with HbA1c data only,
without BMI, expanded the population by only 1.8%. Therefore, we cannot assume that our results are representative of
the entire group. It is impossible to truly know the impact of
deployment on diabetes with the limited information that we
were able to obtain. Even so, by reporting our observations,
it is our hope that pre and postdeployment practices will
evolve such that we can accumulate more data in the future.
It is important that medical questions surrounding SMs with
chronic diseases (like diabetes) who deploy can be definitively
answered. Second, our study did not differentiate between
deployed locations due to policies limiting access to such data.
Some settings are more austere than others, and we were not
able to control for this variability in our data set. Certainly,
a centrally located medical center with full resources in a
deployed setting may be suitable for a SM who uses insulin,
and this environment is very different from a remotely placed
forward operating location. Third, our study did not account
for SM specialty codes. A soldier who travels and engages in
enemy combat operations has different requirements, requiring different limitations, from a uniformed support member
that remains in secure areas “behind the wire.” Accordingly,
our study limitations highlight opportunities for future study.

CONCLUSION
This study provides insight to a readiness issue regarding the
safety of deploying SMs with diabetes, which has previously
been an unexplored area of military medicine. While hesitancy
to deploy this population is prudent, we demonstrated that
HbA1c did not seem to deteriorate after a wide variety of
deployment types and durations. It is encouraging to discover
that most SMs with diabetes deployed with an HbA1c < 7.0%,
which is deemed to reflect the achievement of satisfactory
glycemic targets. Although it is commonly expected that
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at Fort Bragg, North Carolina, described their experiences
providing remote management of U.S. Army soldiers with
type 1 diabetes on insulin pumps or multidose injections,
some of whom performed highly strenuous activities such
as specialized parachute jumps and field training. After
a mean follow-up of 17 months, the soldiers experienced
a remarkable decline in mean HbA1c from 9.6 to 6.6%.
However, their telemedicine model, which provided patients
with 24/7 remote access and up to daily review of glucose data,
would have been very difficult to replicate in a deployment
or a general in-garrison clinical setting.15 Although the
relevant body of literature is highly variegated, it universally
emphasizes that participation in military activities is possible
with comprehensive patient education, assiduous preparation
and self-care, and timely clinical surveillance.
The statistically significant reduction in BMI observed in
the current study was consistent with the prior study conducted by the authors among Air Force personnel.3 Several
other studies have also examined body composition changes
after deployments among SMs, with the most contemporary
studies deriving experiences from deployments to the Middle East.16–23 In reviewing these studies, however, no clear
pattern emerges regarding changes in BMI, lean mass, or fat
mass after a deployment. Substantial heterogeneity in physical
activity, diet, combat tasks, deployment durations, and measurement methods precludes the possibility of arriving at any
conclusion that can explain or predict changes in BMI after
a deployment. In the diabetes population, however, we have
now demonstrated in two studies that BMI tends to decline
over deployments, which we generally view as salutary. In
this study, we demonstrated a sustainment in BMI reduction
for those who deployed up to 315 days. With predeployment
mean BMIs in the overweight range, even a modest reduction
in BMI might have prevented a decrement in glycemic control
or compensated for factors promoting hyperglycemia in a
deployed setting, such as changes in diet, changes in physical
activities, variations in sleep patterns, or lack of timely access
to medications and refills.
We must acknowledge that our study reveals many findings
of considerable significance with potential impact on military
policy. First and foremost, it is astounding that over the course
of 13 years, there have been 11,325 deployments involving
a SM who carried the diagnosis of diabetes mellitus. The
magnitude of this number flies counters to the notion that
many assume to be true, and that diabetes is a disqualifying
condition for service in military deployments. It clearly is not.
Second, the fact that the military endocrinology community is
largely unaware of any adverse clinical patterns involving SMs
who deployed with diabetes suggests that the great majority
are able to function well in the deployed setting. Third, it is
concerning that of the large number of deployments, only 474
(4.2%) of these SMs had an HbA1c and BMI drawn within
90 days prior to and after deployment. There is room for
improvement in how we care for our SMs with diabetes, both
in how we prepare them for deployments and how we ensure
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HbA1c would decline in a population who improved their
BMI, it was not realized in our study population. This paradox
could be due to multiple factors, such as daily routine changes
and physiologic variations that occur in a deployed setting.
Concerning trends included deployment of some SMs with
much higher HbA1c, utilization of medications with less
desirable safety profiles, and the lack of HbA1c and BMI
evaluation proximal to the time of deployment departure and
return. However, for SMs meeting adequate glycemic targets,
we demonstrated that HbA1c remained stable, supporting
the notion that certain SMs may safely deploy with diabetes. Future research endeavors should analyze in a prospective fashion, where a more complete array of diabetes and
readiness-related measures to comprehensively evaluate the
safety of deploying SMs with diabetes.

